Meg Jardine's Publications

Feng KY, Li JW, Ianus J et alii
Reasons for hospitalizations in patients with type 2 diabetes in the CANVAS programme: A secondary analysis
Journal articles
2021
Diabetes
Young TK, Li JW, Kang A et alii
Effects of canagliflozin compared with placebo on major adverse cardiovascular and kidney events in patient groups with different baseline levels of HbA1c, disease duration and treatment intensity: results from the CANVAS Program
Journal articles
2021
Diabetologia
Neuen BL, Oshima M, Perkovic V et alii
Effects of canagliflozin on hyperkalaemia and serum potassium in people with diabetes and chronic kidney disease: insights from the CREDENCE trial
Journal articles
2021
European Heart Journal
Neuen BL, Oshima M, Perkovic V et alii
Effects of canagliflozin on hyperkalaemia and serum potassium in people with diabetes and chronic kidney disease: insights from the CREDENCE trial
Conference Papers
2021
in EUROPEAN HEART JOURNAL
Kang A, Arnold R, Gallagher M et alii
Effect of hemodiafiltration on the progression of neuropathy with kidney failure: A randomized controlled trial
Journal articles
2021
Clinical Journal of the American Society of Nephrology
McGree JM, Hockham C, Kotwal S et alii
Controlled evaLuation of Angiotensin Receptor Blockers for COVID-19 respIraTorY disease (CLARITY): Statistical analysis plan for a randomised controlled Bayesian adaptive sample size trial
Preprints
2021
http://dx.doi.org/10.1101/2021.08.17.21262196
Natale P, Palmer S, Saglimbene V et alii
ANTIPLATELET AGENTS FOR CHRONIC KIDNEY DISEASE: AN UPDATED COCHRANE REVIEW
Conference Papers
2021
in NEPHROLOGY
Jardine M, Wanner C, Nangaku M et alii
MEDIATORS OF THE EMPAGLIFLOZIN TREATMENT EFFECT ON KIDNEY OUTCOMES IN THE EMPA-REG OUTCOME TRIAL
Conference Papers
2021
in NEPHROLOGY
Tiong MK, Krishnasamy R, Smith ER et alii
Effect of a medium cut-off dialyzer on protein-bound uremic toxins and mineral metabolism markers in patients on hemodialysis
Journal articles
2021
Hemodialysis International
Wang KM, Li JW, Bhalla V et alii
Canagliflozin, serum magnesium and cardiovascular outcomes—Analysis from the CANVAS Program
Journal articles
2021
Endocrinology
Arnott C, Li JW, Cannon CP et alii
The effects of canagliflozin on heart failure and cardiovascular death by baseline participant characteristics: Analysis of the CREDENCE trial
Conference Abstracts
2021
in Diabetes
Yi TW, Smyth B, Kang A et alii
Kidney and Cardiovascular Effects of Canagliflozin According to Age and Sex in the CREDENCE Trial
Journal articles
2021
DIABETES
Liao J, Kang A, Xia C et alii
The Impact of Canagliflozin on the Risk of Neuropathy Events: Results from the CREDENCE Trial
Journal articles
2021
DIABETES
Cardoza K, Kang A, Smyth B et alii
Canagliflozin Improves Cardiovascular and Renal Outcomes across Broad Geographic Regions: Results from CREDENCE
Journal articles
2021
DIABETES
Jun M, Harris K, Heerspink HJL et alii
Variability in estimated glomerular filtration rate and the risk of major clinical outcomes in diabetes: Post hoc analysis from the ADVANCE trial
Journal articles
2021
Diabetes
Yu J, Arnott C, Neuen BL et alii
Cardiovascular and renal outcomes with canagliflozin according to baseline diuretic use: a post hoc analysis from the CANVAS Program (vol 8, pg 1482, 2021)
Journal articles
2021
ESC HEART FAILURE
Zhou Z, Jardine MJ, Li Q et alii
Effect of SGLT2 inhibitors on stroke and atrial fibrillation in diabetic kidney disease: Results from the CREDENCE trial and meta-analysis
Journal articles
2021
Stroke
Clase CM, Fu EL, Jardine M et alii
In response
Journal articles
2021
Annals of Internal Medicine
Ng JKC, Smyth B, Marshall MR et alii
Relationship between measured and prescribed dialysate sodium in haemodialysis: A systematic review and meta-Analysis
Journal articles
2021
Nephrology Dialysis Transplantation
Nataatmadja M, Krishnasamy R, Zuo L et alii
Quality of Life in Caregivers of Patients Randomized to Standard- Versus Extended-Hours Hemodialysis
Journal articles
2021
Kidney International Reports
Oshima M, Jardine MJ, Agarwal R et alii
Insights from CREDENCE trial indicate an acute drop in estimated glomerular filtration rate during treatment with canagliflozin with implications for clinical practice
Journal articles
2021
Kidney International
Yu J, Arnott C, Neuen BL et alii
Cardiovascular and renal outcomes with canagliflozin according to baseline diuretic use: a post hoc analysis from the CANVAS Program
Journal articles
2021
ESC Heart Failure
Barisoni L, Barratt J, Campbell K et alii
Innovating and invigorating the clinical trial infrastructure for glomerular diseases
Journal articles
2021
Kidney International
Evans RDR, Smyth B, Levin A et alii
The International Society of Nephrology Advancing Clinical Trials (ISN-ACT) Network: current activities and future goals
Journal articles
2021
Kidney International
Sarraju A, Li JW, Cannon CP et alii
Effects of canagliflozin on cardiovascular, renal, and safety outcomes in participants with type 2 diabetes and chronic kidney disease according to history of heart failure: Results from the CREDENCE trial
Journal articles
2021
American Heart Journal
O'Hara DV, Parkhill TR, Badve SV et alii
The effects of dipeptidyl peptidase-4 inhibitors on kidney outcomes
Journal articles
2021
Diabetes

Previous Next

Meg Jardine's Publications

Reasons for hospitalizations in patients with type 2 diabetes in the CANVAS programme: A secondary analysis

Effects of canagliflozin compared with placebo on major adverse cardiovascular and kidney events in patient groups with different baseline levels of HbA1c, disease duration and treatment intensity: results from the CANVAS Program

Effects of canagliflozin on hyperkalaemia and serum potassium in people with diabetes and chronic kidney disease: insights from the CREDENCE trial

Effects of canagliflozin on hyperkalaemia and serum potassium in people with diabetes and chronic kidney disease: insights from the CREDENCE trial

Effect of hemodiafiltration on the progression of neuropathy with kidney failure: A randomized controlled trial

Controlled evaLuation of Angiotensin Receptor Blockers for COVID-19 respIraTorY disease (CLARITY): Statistical analysis plan for a randomised controlled Bayesian adaptive sample size trial

ANTIPLATELET AGENTS FOR CHRONIC KIDNEY DISEASE: AN UPDATED COCHRANE REVIEW

MEDIATORS OF THE EMPAGLIFLOZIN TREATMENT EFFECT ON KIDNEY OUTCOMES IN THE EMPA-REG OUTCOME TRIAL

Effect of a medium cut-off dialyzer on protein-bound uremic toxins and mineral metabolism markers in patients on hemodialysis

Canagliflozin, serum magnesium and cardiovascular outcomes—Analysis from the CANVAS Program

The effects of canagliflozin on heart failure and cardiovascular death by baseline participant characteristics: Analysis of the CREDENCE trial

Kidney and Cardiovascular Effects of Canagliflozin According to Age and Sex in the CREDENCE Trial

The Impact of Canagliflozin on the Risk of Neuropathy Events: Results from the CREDENCE Trial

Canagliflozin Improves Cardiovascular and Renal Outcomes across Broad Geographic Regions: Results from CREDENCE

Variability in estimated glomerular filtration rate and the risk of major clinical outcomes in diabetes: Post hoc analysis from the ADVANCE trial

Cardiovascular and renal outcomes with canagliflozin according to baseline diuretic use: a post hoc analysis from the CANVAS Program (vol 8, pg 1482, 2021)

Effect of SGLT2 inhibitors on stroke and atrial fibrillation in diabetic kidney disease: Results from the CREDENCE trial and meta-analysis

In response

Relationship between measured and prescribed dialysate sodium in haemodialysis: A systematic review and meta-Analysis

Quality of Life in Caregivers of Patients Randomized to Standard- Versus Extended-Hours Hemodialysis

Insights from CREDENCE trial indicate an acute drop in estimated glomerular filtration rate during treatment with canagliflozin with implications for clinical practice

Cardiovascular and renal outcomes with canagliflozin according to baseline diuretic use: a post hoc analysis from the CANVAS Program

Innovating and invigorating the clinical trial infrastructure for glomerular diseases

The International Society of Nephrology Advancing Clinical Trials (ISN-ACT) Network: current activities and future goals

Effects of canagliflozin on cardiovascular, renal, and safety outcomes in participants with type 2 diabetes and chronic kidney disease according to history of heart failure: Results from the CREDENCE trial

The effects of dipeptidyl peptidase-4 inhibitors on kidney outcomes

The George Institute for Global Health

The George Institute country sites:

Acknowledgement of Country